Is Egrifta (Tesamorelin) Legal in Georgia?
HealthRX.com
Egrifta is prescription-only; Georgia rules are not covered here
Key numbers
- 1.28 mgLabeled once-daily dose of the Egrifta WR product, which is not interchangeable with SVSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 11.6 mgVial strength of Egrifta WR, one of the two current labeled productsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1.4 mgLabeled once-daily dose of the Egrifta SV productSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- FDA status / Prescription drug, application 022505, first approved November 10, 2010 [1]
- Current products / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial) [2][3]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]
- Labeled doses / Egrifta SV 1.4 mg; Egrifta WR 1.28 mg; not substitutable [2][3]
- Georgia-specific rule / Not covered on this page
- Compounding / Appears in no category on FDA's bulk-substance lists [4][5][6]
- Sport / WADA prohibits tesamorelin at all times [7][8]
What makes tesamorelin a prescription drug?
FDA approval. Tesamorelin acetate was first approved November 10, 2010 under application 022505, which FDA later deemed a biologics license application, and Drugs@FDA lists the products as prescription only [1]. The current labels are Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial, both dated July 29, 2026 and both once-daily subcutaneous injections [2][3]. Tesamorelin is a synthetic analog of growth hormone-releasing factor, not growth hormone: it stimulates pituitary GRF receptors, so the pituitary releases the body's own growth hormone and IGF-1 and IGFBP-3 rise [2].
Questions worth asking
What is Egrifta approved to treat?
One thing: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]. The label adds that long-term cardiovascular safety is not established, that continuation should be reconsidered in patients who have not had a reduction in visceral adipose tissue, and that it is not indicated for weight loss because its effect on weight is neutral [2]. Use in people without HIV lipodystrophy sits outside the labeled indication [2].
Sport and the WADA rule
Athletes face a separate limit. WADA's Prohibited List names tesamorelin in S2.2.4 among growth hormone releasing factors and prohibits it at all times, in and out of competition, on both the 2026 and 2027 Lists [7][8].
Compounded tesamorelin
FDA keeps a list of bulk substances that may present significant safety risks (content dated 04/22/2026), a list for state-licensed pharmacies and physicians (updated May 14, 2026) and a list for outsourcing facilities (updated March 21, 2025). Tesamorelin appears in no category on any of them, so FDA has made no category-based statement about compounding it [4][5][6]. Tesamorelin is already a component of an FDA-approved drug, Egrifta [1][2][3]. It is not one of the six peptides in HHS's draft enforcement-discretion policy for compounded peptides filed October 28, 2026 [9][10]. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [11].
Doses and administration
Egrifta SV is 1.4 mg (0.35 mL) once daily; Egrifta WR is 1.28 mg (0.16 mL) once daily, and the labels state the two are not substitutable [2][3]. Both labels describe once-daily abdominal injections with rotating sites; the Egrifta SV label says not to inject into scar tissue, bruises or the navel [2].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is Egrifta legal in Georgia?
Do I need a prescription for tesamorelin?
Is compounded tesamorelin legal in Georgia?
References
Show all 11 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Official web page.
- Official web page.
- Compounding and the FDA: Questions and Answers | FDA.